{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:32:10Z","timestamp":1760236330597,"version":"build-2065373602"},"reference-count":73,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP17H06416","JP19K16076","JP20K21578"],"award-info":[{"award-number":["JP17H06416","JP19K16076","JP20K21578"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Satake Technical Foundation","award":["None"],"award-info":[{"award-number":["None"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Mucopolysaccharidosis type II (MPS II) results from the dysfunction of a lysosomal enzyme, iduronate-2-sulfatase (IDS). Dysfunction of IDS triggers the lysosomal accumulation of its substrates, glycosaminoglycans, leading to mental retardation and systemic symptoms including skeletal deformities and valvular heart disease. Most patients with severe types of MPS II die before the age of 20. The administration of recombinant IDS and transplantation of hematopoietic stem cells are performed as therapies for MPS II. However, these therapies either cannot improve functions of the central nervous system or cause severe side effects, respectively. To date, 729 pathogenetic variants in the IDS gene have been reported. Most of these potentially cause misfolding of the encoded IDS protein. The misfolded IDS mutants accumulate in the endoplasmic reticulum (ER), followed by degradation via ER-associated degradation (ERAD). Inhibition of the ERAD pathway or refolding of IDS mutants by a molecular chaperone enables recovery of the lysosomal localization and enzyme activity of IDS mutants. In this review, we explain the IDS structure and mechanism of activation, and current findings about the mechanism of degradation-dependent loss of function caused by pathogenetic IDS mutation. We also provide a potential therapeutic approach for MPS II based on this loss-of-function mechanism.<\/jats:p>","DOI":"10.3390\/ijms222212227","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T08:10:22Z","timestamp":1636704622000},"page":"12227","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Loss of Function of Mutant IDS Due to Endoplasmic Reticulum-Associated Degradation: New Therapeutic Opportunities for Mucopolysaccharidosis Type II"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0707-9025","authenticated-orcid":false,"given":"Koji","family":"Matsuhisa","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Imaizumi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of Lysosomal Storage Disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","article-title":"Epidemiology of mucopolysaccharidoses","volume":"121","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_3","first-page":"21","article-title":"Molecular basis of iduronate-2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome)","volume":"36","author":"Li","year":"1999","journal-title":"J. Med Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1073\/pnas.70.7.2134","article-title":"The Defect in the Hunter Syndrome: Deficiency of Sulfoiduronate Sulfatase","volume":"70","author":"Bach","year":"1973","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-017-0662-9","article-title":"Open issues in Mucopolysaccharidosis type I-Hurler","volume":"12","author":"Parini","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/GIM.0b013e318211a7e1","article-title":"Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals","volume":"13","author":"Wang","year":"2011","journal-title":"Genet. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Hampe, C., Yund, B., Orchard, P., Lund, T., Wesley, J., and McIvor, R. (2021). Differences in MPS I and MPS II Disease Manifestations. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22157888"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imj.15100","article-title":"Treatable lysosomal storage diseases in the advent of disease-specific therapy","volume":"50","author":"Peters","year":"2020","journal-title":"Intern. Med. J."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Zapolnik, P., and Pyrkosz, A. (2021). Gene Therapy for Mucopolysaccharidosis Type II\u2014A Review of the Current Possibilities. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115490"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses","volume":"50","author":"Muenzer","year":"2011","journal-title":"Rheumatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e1258","DOI":"10.1542\/peds.2010-1274","article-title":"Natural Progression of Neurological Disease in Mucopolysaccharidosis Type II","volume":"127","author":"Holt","year":"2011","journal-title":"Pediatr."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"D\u2019Avanzo, F., Rigon, L., Zanetti, A., and Tomanin, R. (2020). Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041258"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15786","DOI":"10.1038\/ncomms15786","article-title":"Insights into Hunter syndrome from the structure of iduronate-2-sulfatase","volume":"8","author":"Demydchuk","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Saito, S., Ohno, K., Okuyama, T., and Sakuraba, H. (2016). Structural Basis of Mucopolysaccharidosis Type II and Construction of a Database of Mutant Iduronate 2-Sulfatases. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0163964"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.162.3853.570","article-title":"Hurler and Hunter Syndromes: Mutual Correction of the Defect in Cultured Fibroblasts","volume":"162","author":"Fratantoni","year":"1968","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1016\/S0021-9258(19)85586-2","article-title":"Biosynthesis of lysosomal enzymes in fibroblasts. Phosphorylation of mannose residues","volume":"255","author":"Hasilik","year":"1980","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1172-8-42","article-title":"Phase I\/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)","volume":"8","author":"Sohn","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/GIM.0b013e318206786f","article-title":"Idursulfase treatment of Hunter syndrome in children younger than 6 years: Results from the Hunter Outcome Survey","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"ref_20","first-page":"65","article-title":"Enzymatic replacement therapy for Hunter disease: Up to 9years experience with 17 patients","volume":"3","author":"Parini","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_21","first-page":"39","article-title":"Current and Emerging Therapies for Mucopolysaccharidoses","volume":"261","author":"Lagler","year":"2019","journal-title":"Physiol. Pharmacol. Bone"},{"key":"ref_22","first-page":"31","article-title":"Bone marrow transplantation in Hunter syndrome: A preliminary report","volume":"22","author":"Warkentin","year":"1986","journal-title":"Birth Defects Orig. Artic. Ser."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.bmt.1702397","article-title":"Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia","volume":"25","author":"Mullen","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1365-2141.2009.07974.x","article-title":"Cord blood and bone marrow transplantation in inherited metabolic diseases: Scientific basis, current status and future directions","volume":"148","author":"Prasad","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic Cell Transplantation for Mucopolysaccharidosis Patients Is Safe and Effective: Results after Implementation of International Guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","article-title":"Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: A nationwide survey in Japan","volume":"107","author":"Tanaka","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ymthe.2017.03.025","article-title":"Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications","volume":"25","author":"Biffi","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood-2014-11-606681","article-title":"Early HSCT corrects the skeleton in MPS","volume":"125","author":"Kurtzberg","year":"2015","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1042\/bj2710075","article-title":"Human liver iduronate-2-sulphatase. Purification, characterization and catalytic properties","volume":"271","author":"Bielicki","year":"1990","journal-title":"Biochem. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1073\/pnas.87.21.8531","article-title":"Hunter syndrome: Isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA","volume":"87","author":"Wilson","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1042\/bj3260243","article-title":"Characterization of iduronate sulphatase mutants affecting N-glycosylation sites and the cysteine-84 residue","volume":"326","author":"Millat","year":"1997","journal-title":"Biochem. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0092-8674(95)90314-3","article-title":"A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency","volume":"82","author":"Schmidt","year":"1995","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/bj3090425","article-title":"Processing of iduronate 2-sulphatase in human fibroblasts","volume":"309","author":"Froissart","year":"1995","journal-title":"Biochem. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10545-006-0440-7","article-title":"Effect of Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of iduronate-2-sulfatase: Enzymatic activity, protein processing and structural analysis","volume":"29","author":"Kato","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e01667","DOI":"10.1016\/j.heliyon.2019.e01667","article-title":"Identification of the iduronate-2-sulfatase proteome in wild-type mouse brain","volume":"5","author":"Cardona","year":"2019","journal-title":"Heliyon"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.yexcr.2019.04.021","article-title":"Modelling the neuropathology of lysosomal storage disorders through disease-specific human induced pluripotent stem cells","volume":"380","author":"Molnar","year":"2019","journal-title":"Exp. Cell Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0092-8674(01)00611-0","article-title":"XBP1 mRNA Is Induced by ATF6 and Spliced by IRE1 in Response to ER Stress to Produce a Highly Active Transcription Factor","volume":"107","author":"Yoshida","year":"2001","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1042\/BCJ20160582","article-title":"The evolving role of ubiquitin modification in endoplasmic reticulum-associated degradation","volume":"474","author":"Preston","year":"2017","journal-title":"Biochem. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-018-0871-8","article-title":"Shutdown of ER-associated degradation pathway rescues functions of mutant iduronate 2-sulfatase linked to mucopolysaccharidosis type II","volume":"9","author":"Osaki","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bbrc.2019.04.115","article-title":"Calnexin promotes the folding of mutant iduronate 2-sulfatase related to mucopolysaccharidosis type II","volume":"514","author":"Osaki","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/mt.2015.62","article-title":"Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders","volume":"23","author":"Parenti","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/dna.2019.5221","article-title":"Endoplasmic Reticulum and Lysosomal Quality Control of Four Nonsense Mutants of Iduronate 2-Sulfatase Linked to Hunter\u2019s Syndrome","volume":"39","author":"Marazza","year":"2020","journal-title":"DNA Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/tra.12358","article-title":"N-Glycan-based ER Molecular Chaperone and Protein Quality Control System: The Calnexin Binding Cycle","volume":"17","author":"Lamriben","year":"2016","journal-title":"Traffic"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1042\/EBC20160003","article-title":"Protein quality control at the endoplasmic reticulum","volume":"60","author":"McCaffrey","year":"2016","journal-title":"Essays Biochem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.semcdb.2010.03.006","article-title":"Protein quality control in the ER: The recognition of misfolded proteins","volume":"21","author":"Gehring","year":"2010","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1172\/JCI0216886","article-title":"Orchestrating the unfolded protein response in health and disease","volume":"110","author":"Kaufman","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1172\/JCI0216784","article-title":"Translational control in the endoplasmic reticulum stress response","volume":"110","author":"Ron","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41574-021-00510-4","article-title":"Therapeutic opportunities for pancreatic \u03b2-cell ER stress in diabetes mellitus","volume":"17","author":"Yong","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/febs.14332","article-title":"Emerging roles of ER stress in the etiology and pathogenesis of Alzheimer\u2019s disease","volume":"285","author":"Gerakis","year":"2018","journal-title":"FEBS J."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Losada D\u00edaz, J., Cepeda Del, C.J., Rodriguez-L\u00f3pez, E., and Alm\u00e9ciga-D\u00edaz, C. (2019). Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses. Int. J. Mol. Sci., 21.","DOI":"10.20944\/preprints201910.0365.v1"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymgme.2017.12.428","article-title":"Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II","volume":"123","author":"Hoshina","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S2213-8587(19)30006-3","article-title":"& Spotlight on rare diseases","volume":"7","author":"Endocrinology","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Pei, J., Kinch, L., Otwinowski, Z., and Grishin, N.V. (2020). Mutation severity spectrum of rare alleles in the human genome is predictive of disease type. PLoS Comput. Biol., 16.","DOI":"10.1371\/journal.pcbi.1007775"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.chembiol.2014.06.008","article-title":"ERdj3 Is an Endoplasmic Reticulum Degradation Factor for Mutant Glucocerebrosidase Variants Linked to Gaucher\u2019s Disease","volume":"21","author":"Tan","year":"2014","journal-title":"Chem. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Fog, C., Zago, P., Malini, E., Solanko, L., Peruzzo, P., Bornaes, C., Magnoni, R., Mehmedbasic, A., Petersen, N., and Bembi, B. (2018). The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase. EBioMedicine, 38.","DOI":"10.1016\/j.ebiom.2018.11.037"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: Biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","author":"Ishii","year":"2007","journal-title":"Biochem. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med Genet."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1091\/mbc.E16-01-0012","article-title":"Tay\u2013Sachs disease mutations in HEXA target the \u03b1 chain of hexosaminidase A to endoplasmic reticulum\u2013associated degradation","volume":"27","author":"Dersh","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"C259","DOI":"10.1152\/ajpcell.2000.278.2.C259","article-title":"Sodium 4-phenylbutyrate downregulates Hsc70: Implications for intracellular trafficking of \u0394F508-CFTR","volume":"278","author":"Rubenstein","year":"2000","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/emboj\/18.6.1492","article-title":"The Hdj-2\/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis","volume":"18","author":"Meacham","year":"1999","journal-title":"EMBO J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0092-8674(95)90240-6","article-title":"Degradation of CFTR by the ubiquitin-proteasome pathway","volume":"83","author":"Ward","year":"1995","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/humu.10041","article-title":"Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screening","volume":"19","author":"Bobadilla","year":"2002","journal-title":"Hum. Mutat."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1097\/01.ASN.0000027355.41663.14","article-title":"Cell-Biologic and Functional Analyses of Five NewAquaporin-2Missense Mutations that Cause Recessive Nephrogenic Diabetes Insipidus","volume":"13","author":"Marr","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s12035-014-8881-8","article-title":"Robust Endoplasmic Reticulum-Associated Degradation of Rhodopsin Precedes Retinal Degeneration","volume":"52","author":"Chiang","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"ref_68","first-page":"424","article-title":"Clearance of RhodopsinP23H aggregates requires the ERAD effector VCP","volume":"1803","author":"Griciuc","year":"2010","journal-title":"Biochim. Biophys. Acta (BBA) -Bioenerg."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Wang, Y.-J., Tayo, B.O., Bandyopadhyay, A., Wang, H., Feng, T., Franceschini, N., Tang, H., Gao, J., Sung, Y.J., and Elston, R.C. (2014). The Association of the Vanin-1 N131S Variant with Blood Pressure Is Mediated by Endoplasmic Reticulum-Associated Degradation and Loss of Function. PLoS Genet., 10.","DOI":"10.1371\/journal.pgen.1004641"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"19743","DOI":"10.1074\/jbc.M115.647685","article-title":"Rescuing Trafficking Mutants of the ATP-binding Cassette Protein, ABCA4, with Small Molecule Correctors as a Treatment for Stargardt Eye Disease","volume":"290","author":"Sabirzhanova","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.1038\/srep06992","article-title":"Rer1 and calnexin regulate endoplasmic reticulum retention of a peripheral myelin protein 22 mutant that causes type 1A Charcot-Marie-Tooth disease","volume":"4","author":"Hara","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1074\/jbc.M115.702514","article-title":"OS9 Protein Interacts with Na-K-2Cl Co-transporter (NKCC2) and Targets Its Immature Form for the Endoplasmic Reticulum-associated Degradation Pathway","volume":"291","author":"Seaayfan","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI96420","article-title":"Hypothalamic ER\u2013associated degradation regulates POMC maturation, feeding, and age-associated obesity","volume":"128","author":"Kim","year":"2018","journal-title":"J. Clin. Investig."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/22\/12227\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:29:08Z","timestamp":1760167748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/22\/12227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"references-count":73,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["ijms222212227"],"URL":"https:\/\/doi.org\/10.3390\/ijms222212227","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2021,11,12]]}}}